Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future
| Autor: | Hassan El-Bakkar, Maher Abdul-Hay, Anjali Varma Desai |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Cancer Research
Chronic lymphocytic leukemia Receptors Antigen T-Cell Antineoplastic Agents Pyridinium Compounds Antibodies Monoclonal Humanized Cyclic N-Oxides chemistry.chemical_compound Piperidines immune system diseases Obinutuzumab hemic and lymphatic diseases medicine Bruton's tyrosine kinase Humans Immunologic Factors Dinaciclib Lenalidomide Protein Kinase Inhibitors Quinazolinones Flavonoids Sulfonamides Aniline Compounds biology business.industry Adenine Indolizines Hematology medicine.disease Bridged Bicyclo Compounds Heterocyclic Isoquinolines Leukemia Lymphocytic Chronic B-Cell Chimeric antigen receptor Thalidomide Pyrimidines Oncology chemistry Proto-Oncogene Proteins c-bcl-2 Purines Ibrutinib Immunology biology.protein Pyrazoles business Idelalisib medicine.drug |
| Zdroj: | Clinical lymphoma, myelomaleukemia. 15(6) |
| ISSN: | 2152-2669 |
| Popis: | Half of a century ago, physicians managing chronic lymphocytic leukemia (CLL) recognized some of its presenting features such as lymphocytosis, lymphadenopathy, and splenomegaly. Subsequently, an enhanced understanding of the disease mechanisms involved in CLL led to new, more targeted treatments. There is now a plethora of treatments available for CLL. In this review article we discuss in detail several of the novel agents that are being studied or approved for the treatment of CLL including: phosphatidylinositol 3-kinase inhibitors (idelalisib and IPI-145), Bruton tyrosine kinase inhibitors (ibrutinib), B cell lymphoma 2 inhibitors (ABT-263 and ABT-199), new anti-CD20 monoclonal antibodies (obinutuzumab), cyclin-dependent kinase inhibitors (flavopiridol and dinaciclib), immunomodulators (lenalidomide) and chimeric antigen receptor T-cell therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect